BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental d...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Cancer
Päätekijät: Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2015
Aiheet:
Translational Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522629/
https://ncbi.nlm.nih.gov/pubmed/26180923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.220
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia